and is internalized by receptor-mediated endocytosis [3, 4] . productive HIV-1 infections, questions exist about the infectivmM L-glutamine, 50 U/mL penicillin, 50 mg/mL streptomycin, and ity of the target cell cytosol. In addition, some reports indicate 15% heat-inactivated fetal bovine serum. OKT3 (Ortho Diagnostics, Raritan, NJ) was added at concentrations found to be optimal.
duction in acutely infected peripheral blood mononuclear cell IL), were 0.196 and 0.322 mg/mL, respectively. Evaluated by a (PBMC) cultures [1, 2] . DAB 389 IL-2 binds to the high-affinity protein synthesis inhibition bioassay, specific activities of these interleukin (IL)-2 receptor (IL-2R) on the target cell surface lots were comparable.
and is internalized by receptor-mediated endocytosis [3, 4] . productive HIV-1 infections, questions exist about the infectivmM L-glutamine, 50 U/mL penicillin, 50 mg/mL streptomycin, and ity of the target cell cytosol. In addition, some reports indicate 15% heat-inactivated fetal bovine serum. OKT3 (Ortho Diagnostics, Raritan, NJ) was added at concentrations found to be optimal.
that the IL-2R on the host cell may be down-regulated during After a 72-h incubation in a 5% CO 2 -humidified atmosphere at the course of HIV infection [5 -8] . Should this be the case, 37ЊC, cells were washed and dispensed (10 5 cells, 100 mL) into down-regulation of the IL-2R on an infected cell may interfere microtiter wells containing DAB 389 IL-2, recombinant (r)  with the ability of DAB 389 IL-2 to display anti-HIV activity. When the same concentrations of DAB 389 IL-2 were added to cultures after the virus had been allowed to replicate for 5 days, DAB 389 IL-2 consistently inhibited infectious virus production in a dose-dependent manner regardless of whether total virus in the system or the amount of virus specifically released into culture supernatants was measured. Relative to cultures in which DAB 389 IL-2 was added immediately after infection, however, increased concentrations of fusion protein were required to comparably suppress infectious virus production.
Neither mutational variant of DAB 389 IL-2 could inhibit the replication of infectious virus, even when added at doses as high as 10 09 M. These data indicate that the anti-HIV activity of DAB 389 IL-2 is specifically directed at the IL-2R on HIV-1 -infected cells and requires an active catalytic moiety on the fusion protein for its expression.
p24 antigen production and its inhibition by DAB 389 IL-2 in extended acute infections. On various days after an acute infection, DAB 389 IL-2 was added to the cultures of HIV-1 -infected PBMC, and levels of p24 antigen were assessed 72 h later. Dose-dependent inhibition of p24 antigen production was the inhibition of p24 antigen production.
The p24 antigen production in HIV-1 -infected PBMC that had not been deliberately activated by mitogen prior to infec-PBMC cultures that had been treated with DAB 389 IL-2 immedition was exceedingly low at all time points tested. However, ately after infection (table 1) . Untreated control cell suspen-DAB 389 IL-2 added at doses §10 011 M significantly inhibited sions contained ú5608 IUPM, a value that represents the upper p24 antigen production in day 8 postinfection cultures. The dose-dependent inhibition of p24 antigen expression by limit of quantifiable virus in the assay. NOTE. PHA, phytohemagglutinin; ND, not done. p24 antigen levels (ng/mL) were measured in culture supernatants 72 h after addition of DAB 389 IL-2. * Day DAB 389 IL-2 added after infection. † P for effect of DAB 389 IL-2 concentration on inhibition of p24 antigen production, adjusting for days. ‡ P for overall effect of day on p24 antigen production, adjusting for DAB 389 IL-2 concentration.
DAB 389 IL-2 showed a significant association of increasing efThe addition of DAB 389 IL-2 to activated HIV-1 -infected human PBMC resulted in greatly diminished viral replication ficiency by days. The two mutational variants of DAB 389 IL-2 had no inhibitory effect on p24 antigen production in cultures and release of infectious virus. When added on the day of HIV-1 infection, DAB 389 IL-2 (10 09 M) inhibited the production and of either mitogenically stimulated or unstimulated HIV-1 -infected PBMC.
release of ú99.9% of the infectious virus produced by control cultures. Although delaying the addition of the IL-2 fusion protein by 5 days permitted the replication of more virus by the infected cells, DAB 389 IL-2 (10 09 M) was nevertheless able Discussion to inhibit 94% of the total infectious virus production and In this study, we evaluated the ability of DAB 389 IL-2 to 99.9% of the infectious virus release. Similar results were obreduce infectious virus production in HIV-1 -infected normal served in extended acute infections in which viral replication human PBMC. The results described herein confirm and extend was assessed by production of p24 antigen. In these studies, earlier observations that the IL-2 fusion proteins, DAB 486 IL-2 DAB 389 IL-2 treatment (10 09 M) of activated PBMC 3 days and DAB 389 IL-2, decrease HIV-1 replication in virally infected after HIV-1 infection reduced p24 antigen production to 2.5% PBMC in a dose-dependent and IL-2R -specific manner [1, 2] .
of that of control cultures. The addition of 10 09 M DAB 389 ILIn those studies, HIV-1 mRNA and p24 antigen production 2 as late as 8 days after HIV-1 infection still resulted in inhibiwere inhibited in PBMC infected with an HIV-1 laboratory tion of 52% of p24 antigen production. strain, fresh clinical isolates, and a zidovudine-resistant strain.
The antiviral effects associated with DAB 389 IL-2 treatment of The present study was designed to evaluate two aspects of HIV-infected PBMC were dose-related in both assay systems and DAB 389 IL-2 antiviral activity, including the ability to reduce required a catalytically active fusion protein that could bind to the levels of infectious virus released from cells at an early the IL-2R. Mutational variants of DAB 389 IL-2 that either had and late time point after infection and the ability to inhibit viral impaired catalytic activity (DA glu53 B 389 IL-2) or impaired IL-2R replication at various points during an extended acute infection.
binding (DAB 389 IL-2 D8-19 ) were unable to inhibit the production The two assays used in this study have been commonly used of either infectious virus or p24 antigen. These observations are to identify surrogate markers for evaluating drug efficacy in consistent with those from our studies of the mutational variants of DAB 389 IL-2 in activated human PBMC, in which we showed numerous clinical studies.
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